General Info

OXIS International develops technologies and products used for the research, diagnosis, treatment and prevention of diseases caused by the oxidative stress associated with damage from free radical and reactive oxygen species. The company offers more than 80 research products that are used in testing for oxidative, antioxidant, nitrosative and inflammatory biomarkers, which are thought to play a central role in many human degenerative diseases, including cancer, diabetes, atherosclerosis, stroke, Alzheimer disease, Parkinson disease and amyotrophic lateral sclerosis. The company holds the rights to three therapeutic classes of compounds in the area of oxidative stress and has focused commercialization programs in clinical cardiovascular markers, including myeloperoxidase and glutathione peroxidase, as well as a highly potent antioxidant, ergothioneine. OXIS International is headquartered in Portland, Ore.